MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status: | Recruiting |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 101 |
Updated: | 3/13/2019 |
Start Date: | July 24, 2015 |
End Date: | February 1, 2021 |
Contact: | AstraZeneca Clinical Study Information Center |
Email: | information.center@astrazeneca.com |
Phone: | 1-877-240-9479 |
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in
Adult Subjects with Select Advanced Solid Tumors
Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in
Adult Subjects with Select Advanced Solid Tumors
Inclusion Criteria:
- Adult subjects; age ≥ 18
- Written and signed informed consent must be obtained
- Have histologic or cytologic documentation of solid tumor including EGFR mutated
(EGFRm) NSCLC
- Subjects must have at least 1 lesion that is measureable using RECIST guidelines
- Subjects must consent to provide archived tumor specimens or tumor biopsies for
correlative biomarker studies.
- Eastern Cooperative Oncology Group performance score of 0 or 1
- Adequate organ function
Exclusion Criteria:
- Prior treatment with tumor necrosis factor receptor superfamily agonists including
OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, anti
PDL-1 and anti PDL-1.
- Subjects who have received prior therapy with regimens containing CTLA-4, PD-L1, or
PD-1 antagonists may be permitted to enroll under certain conditions
- Cardiac or peripheral vascular disease meeting any of the following criteria:
- Past history of myocardial infarction in the prior 12 months
- Past history of stroke or transient ischemic attack requiring medical therapy
- Congestive heart failure ≥ Class 3 based on New York Heart Association Functional
Classification
- Grade 3 or greater edema (eg, peripheral, pulmonary)
- History of Grade 3 or greater thromboembolic events in the prior 12 months
- Subjects with active tuberculosis are ineligible. In settings where there is clinical
or radiographic evidence of tuberculosis, active disease must be ruled out
- Active or prior documented autoimmune or inflammatory disorders
- Untreated central nervous system (CNS) metastatic disease
- Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B
or active hepatitis A or C
- Other invasive malignancy within 2 years except for noninvasive malignancies such as
cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the
skin, ductal carcinoma in situ of the breast that has been surgically cured
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, active peptic ulcer disease or gastritis, uncontrolled hypertension,
uncontrolled diabetes, or psychiatric illness/social situations that would limit
compliance with study requirement
We found this trial at
12
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials